Cargando…

Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus

Surgical management of renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus is inherently complex, posing challenges for even the most experienced urologists. Until the mid-2000s, nephrectomy with IVC thrombectomy was exclusively performed using variations of the open technique initiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Masic, Selma, Smaldone, Marc C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185684/
https://www.ncbi.nlm.nih.gov/pubmed/34159102
http://dx.doi.org/10.21037/tau.2019.06.15
_version_ 1783704836206755840
author Masic, Selma
Smaldone, Marc C.
author_facet Masic, Selma
Smaldone, Marc C.
author_sort Masic, Selma
collection PubMed
description Surgical management of renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus is inherently complex, posing challenges for even the most experienced urologists. Until the mid-2000s, nephrectomy with IVC thrombectomy was exclusively performed using variations of the open technique initially described decades earlier, but since then several institutions have reported their robotic experiences. Robotic IVC thrombectomy was initially reported for level I and II thrombi, and more recently in higher-lever III thrombi. In general, the robotic approach is associated with less blood loss and shorter hospital stays compared to the open approach, low rates of open conversion in reported cases, relatively low rates of high-grade complications, and favorable overall survival on short-term follow-up in limited cohorts. Operative times are longer, costs are significantly higher, and left-sided tumors always require intraoperative repositioning and usually require preoperative embolization. To date, criteria for patient selection or open conversion have not been defined, and long-term oncologic outcomes are lacking. While the early published robotic experience demonstrates feasibility and safety in carefully selected patients, longer-term follow-up remains necessary. Patient selection, indications for open conversion, logistics of conversion particularly in emergent settings, necessity and safety of preoperative embolization, the value proposition, and long-term oncologic outcomes must all be clearly defined before this approach is widely adopted.
format Online
Article
Text
id pubmed-8185684
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-81856842021-06-21 Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus Masic, Selma Smaldone, Marc C. Transl Androl Urol Review Article on Controversies in Minimally Invasive Urologic Oncology Surgical management of renal cell carcinoma (RCC) with inferior vena cava (IVC) thrombus is inherently complex, posing challenges for even the most experienced urologists. Until the mid-2000s, nephrectomy with IVC thrombectomy was exclusively performed using variations of the open technique initially described decades earlier, but since then several institutions have reported their robotic experiences. Robotic IVC thrombectomy was initially reported for level I and II thrombi, and more recently in higher-lever III thrombi. In general, the robotic approach is associated with less blood loss and shorter hospital stays compared to the open approach, low rates of open conversion in reported cases, relatively low rates of high-grade complications, and favorable overall survival on short-term follow-up in limited cohorts. Operative times are longer, costs are significantly higher, and left-sided tumors always require intraoperative repositioning and usually require preoperative embolization. To date, criteria for patient selection or open conversion have not been defined, and long-term oncologic outcomes are lacking. While the early published robotic experience demonstrates feasibility and safety in carefully selected patients, longer-term follow-up remains necessary. Patient selection, indications for open conversion, logistics of conversion particularly in emergent settings, necessity and safety of preoperative embolization, the value proposition, and long-term oncologic outcomes must all be clearly defined before this approach is widely adopted. AME Publishing Company 2021-05 /pmc/articles/PMC8185684/ /pubmed/34159102 http://dx.doi.org/10.21037/tau.2019.06.15 Text en 2021 Translational Andrology and Urology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article on Controversies in Minimally Invasive Urologic Oncology
Masic, Selma
Smaldone, Marc C.
Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
title Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
title_full Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
title_fullStr Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
title_full_unstemmed Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
title_short Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
title_sort robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus
topic Review Article on Controversies in Minimally Invasive Urologic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185684/
https://www.ncbi.nlm.nih.gov/pubmed/34159102
http://dx.doi.org/10.21037/tau.2019.06.15
work_keys_str_mv AT masicselma roboticrenalsurgeryforrenalcellcarcinomawithinferiorvenacavathrombus
AT smaldonemarcc roboticrenalsurgeryforrenalcellcarcinomawithinferiorvenacavathrombus